Q: re: Neptune (NTB on the TSX)
This company has been pumped for years, but seems to be developing a niche in the nascent nutraceutical krill oil market (offering strong competition to the huge and traditional fish oil
supplement market). It has however disappointed in the functional food market (no deal with Nestle or Yoplait, which were touted for years - and an anemic relationship, so far, with Bayer).
My question is (I am off the opinion that their nutraceutical business is a long-term winner) if their subsidiary Acasti does NOT prove successful in their clinical trials with their prospective pharmaceutical, Capre, what would the fair market value be of NTB shares likely be (the share price is pumping upward, as I type).
Thanks....
This company has been pumped for years, but seems to be developing a niche in the nascent nutraceutical krill oil market (offering strong competition to the huge and traditional fish oil
supplement market). It has however disappointed in the functional food market (no deal with Nestle or Yoplait, which were touted for years - and an anemic relationship, so far, with Bayer).
My question is (I am off the opinion that their nutraceutical business is a long-term winner) if their subsidiary Acasti does NOT prove successful in their clinical trials with their prospective pharmaceutical, Capre, what would the fair market value be of NTB shares likely be (the share price is pumping upward, as I type).
Thanks....